Roche provides update on astegolimab in chronic obstructive pulmonary disease
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
Subscribe To Our Newsletter & Stay Updated